Zynex develops, manufactures, markets and sells medical devices used for nerve stimulation, pain management, and rehabilitation, as well as non-invasive fluid, sepsis, and laser-based pulse oximetry ...

Fintel reports that on March 12, 2025, Ladenburg Thalmann downgraded their outlook for Zynex (NasdaqGS:ZYXI) from Buy to ...

Fintel reports that on March 12, 2025, RBC Capital downgraded their outlook for Zynex (NasdaqGS:ZYXI) from Outperform to ...

Zynex (NASDAQ:ZYXI – Get Free Report) had its price objective lowered by equities researchers at HC Wainwright from $17.00 to $15.00 in a research note issued on Wednesday,Benzinga reports. The ...

Despite a net loss and TRICARE payment suspension, Zynex Inc (ZYXI) shows resilience with revenue growth and strategic ...

RBC Capital downgraded Zynex (ZYXI) to Sector Perform from Outperform with a price target of $5.50, down from $11. The firm says the company’s ...

Zynex specializes in non-invasive pain management and patient monitoring, with promising advancements. Read why I think ZYXI ...

Zynex, Inc. ( NASDAQ:ZYXI ) just released its latest full-year report and things are not looking great. It wasn't ...

Zynex (ZYXI) stock drops as RBC Capital Market downgrades following the company's Q4 2024 earnings report. Read more here.

Law Offices of Howard G. Smith announces an investigation on behalf of Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) investors concerning the Company's possible violations of federal ...

Zynex Inc. (ZYXI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of $0.09. This compares to earnings of $0.04 per share a year ago. These figures are ...

The Law Offices of Frank R. Cruz announces an investigation of Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) on behalf of investors concerning the Company's possible violations of federal ...